Trontinemab is a very exciting experimental drug, showing great promise in rapidly clearing Alzheimer’s amyloid plaques from the brains of affected individuals, with remarkably little side effects.
See why Cognito’s headset received FDA Breakthrough Device Designation for addressing cognitive and functional symptoms associated with Alzheimer’s.
Walk through the various steps that occur as a person participates in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project.
“It is exciting to see efficacy of potential new drugs for Dementia with Lewy Bodies, the most common dementia after Alzheimer’s. It is a huge area of unmet need,” said Dr. Marwan Sabbagh.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
Doctors routinely diagnose and track dementia. “Neuropsychological tests” are non-invasive, using interviews or paper/pen tests. More invasive diagnostics include powerful MRI and PET scans.
The new Alzheimer’s injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the next level with a simpler pill. Mastinimab fights Alzheimer’s via a revolutionary mechanism of action. Learn why the FDA approved Mastinimab’s final round of trials.
CLINICAL TRIALS VIDEO: Thin electrical wires were surgically implanted in the brain of Alzheimer’s patients. Called “Deep Brain Stimulation”, see how this brain “pacemaker” improves
VIDEO + ARTICLE: An award-winning director joins the nation’s largest independent registered investment advisory firm to film a documentary on clinical trials by diet guru
Anticholinergic drugs have been consistently linked to cognitive impairment. Scientists seek de-prescribing trials to test anticholinergic drugs as reversible risk factors for dementia. Can de-prescribing
INNOVATION – VIDEO: A big supermarket launched a ‘relaxed’ checkout lane to make life a little less stressful for people with dementia and other vulnerable people.
VIDEO + ARTICLE: Residential areas with more green space were associated with faster thinking, better attention, and higher overall cognitive function in a federal study. Learn more.
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
